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A B S T R A C T
Purpose
To assess whether the interval from primary surgery to the start of taxane- plus platinum-based
chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients.
Patients and Methods
The study was conducted on 313 patients who underwent surgery followed by taxane- plus
platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range,
6 to 109 months).
Results
The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy
were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a
pathologic complete response at second-look surgery and 98 obtained a clinical complete
response but were not submitted to second-look surgery. Taking into consideration the best
assessed response, a complete (either clinical or pathologic) response was found in 200
patients. Residual disease ( 1 v 1 cm; P .0001) and ascites (absent v present; P .003)
were independent predictive factors for achieving a complete response, whereas residual
disease (P  .001) and stage (IIc to III v IV; P  .04) were independent prognostic variables
for survival. Conversely, statistical analyses failed to detect significant differences in
complete response rates and survival among patients with an interval from surgery to
chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days.
Conclusion
The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems
to have neither a predictive value for response to treatment nor a prognostic relevance for
survival of advanced ovarian cancer patients.
J Clin Oncol 23:751-758. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Advanced epithelial ovarian cancer is the
most lethal gynecologic cancer. According
to the International Federation of Gynecol-
ogy and Obstetrics (FIGO) Annual Report
No. 24, the 5-year survival was 58.5% for
stage IIIa, 39.9% for stage IIIb, 28.7% for
stage IIIc, and 16.8% for stage IV disease.1
Residual disease after initial surgery,2-6 tu-
mor grade,3-5 and histologic types2,3,5,7 are
the most commonly assessed clinicopatho-
logic variables influencing the response rate
to chemotherapy and survival rate. Re-
cently, many efforts have been made to
identify biologic parameters, such as DNA
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ploidy,3,8,9 oncogenes and tumor suppressor genes,8-15
growth factors and growth factor receptors,9,16,17 and de-
gree of tumor angiogenesis,18-21 that have a predictive or
prognostic value for advanced epithelial ovarian cancer.
Some experimental investigations on different animal
models showed that the removal of the primary tumor
accelerated metastatic tumor growth assessed as both gross
tumor size and metastatic cell kinetics.22-26 The increase in
tumor growth is probably due to a conversion of noncycling
cells in G0 phase into proliferation.
26 However, limited and
conflicting data are currently available about the relation-
ship between the time interval from surgery to the start of
chemotherapy and treatment effectiveness in animal tumor
models,27-29 and in human malignancies including epithe-
lial ovarian cancer.30-35
The aim of this retrospective investigationwas to assess
whether the length of the interval from primary surgery to
taxane- plus platinum-based chemotherapy has any impact
on response to treatment and survival of patients with ad-
vanced epithelial ovarian cancer.
PATIENTS AND METHODS
This retrospective study was conducted on 313 patients who un-
derwent primary surgery followed by taxane- plus platinum-based
chemotherapy for advanced epithelial ovarian cancer at the De-
partments of Gynecology and Obstetrics of University of Brescia,
Pisa, and Turin, and at the Department of Gynecologic Oncology
of the European Institute of Oncology of Milan (Italy) between
January 1994 and January 2003.
The tumor stage and histologic diagnosis of each patient were
determined according to FIGO criteria and the histologic typing
system of the WHO, respectively. Tumors were graded as well
(G1), moderately (G2), or poorly (G3) differentiated.
The planned combination chemotherapy consisted of six
cycles of paclitaxel plus carboplatin in 258 patients, epirubicin plus
paclitaxel plus carboplatin in 18 patients, docetaxel plus carbopla-
tin in 15 patients, ifosfamide plus paclitaxel plus cisplatin in 10
patients, paclitaxel plus cisplatin in seven patients, and epirubicin
plus paclitaxel plus cisplatin in five patients.
Theevaluationof theclinical courseofdiseasewasbasedonclin-
ical examination, serumCA-125 assay, chest x-ray, abdominal-pelvic
ultrasound, and computed tomography scan. Additional investiga-
tions were performed when appropriate. After the sixth cycle of che-
motherapy, patients with no evidence of disease at clinical, serologic,
sonographic, and radiologic examinations were defined as being in
clinical complete response. Three to 5 weeks after the end of chemo-
therapy, a second-look surgery was usually proposed to clinically
complete responders, mostly to patients enrolled onto clinical
trials. A pathologic complete response at second-look surgery
was defined as the disappearance of all macroscopic tumor
deposits with negative peritoneal washing and negative multi-
ple random biopsies. All patients with clinically or surgically
detectable persistent disease, as well as some pathologically
complete responders, received additional chemotherapy.
All patients were observed until they died or until July 2003.
The median follow-up of survivors was 30.7 months (range, 6 to
109 months).
The SAS statistical package (release 8.2; SAS Institute, Cary,
NC) was used for computations.
Time intervals from primary surgery to the start of chemo-
therapy were related to tumor stage, residual disease, and presence
or absence of ascites using the median test.
Rates of complete response were compared to explicative
variables using Pearson’s 2 test (or two-tailed Fisher’s exact test
when appropriate). Multiple logistic regression was carried out to
investigate the relationship among the probability of achieving a
complete response and the explanatory variables.
The cumulative probability of overall survival from the time
of initial surgery was estimated by the product-limit method. The
log-rank test was used to compare the homogeneity of survival
functions across strata defined by categories of prognostic vari-
ables. The relationship between time interval from primary sur-
gery to the start of chemotherapy and overall survival was also
estimated using the nonparametric Spearman rank correlation
coefficient (computed on unrecorded values). A multiple regres-
sion analysis based on the Cox proportional hazards model was
used to test jointly the relative importance of variables as predic-
tors of survival times.
RESULTS
The median age of patients was 56 years (range, 23 to 77
years). According to the FIGO classification, tumor stage
was IIc in 24 patients, III in 249 patients, and IV in 40
patients. Histologically, 205 carcinomas were serous, 35
were endometrioid, 29 were undifferentiated, 26 were
mixed, 13 were clear-cell, four weremucinous, and one was
a malignant Brenner tumor. Tumor grade was G1 in eight
patients, G2 in 82 patients, and G3 in 223 patients. After
initial surgery, 138 patients had residual disease 1 cm and
175 patients had a larger residual tumor. Ascites was de-
tected in 217 patients. Time intervals from primary surgery
to the start of chemotherapy ranged from 3 to 62 days. The
25%, 50%, and 75% quantiles of intervals from primary
surgery to the start of chemotherapy were 11, 21, and 31
days, respectively.
Time intervals from primary surgery to the start of
chemotherapy were not related to residual disease ( 1 v
 1 cm; median, 20 v 22 days; range, 5 to 62 v 3 to 60 days;
P  not significant [ns]) or absence or presence of ascites
(median, 22.5 v 20 days; range, 6 to 60 v 3 to 62 days;
P  ns). Conversely, time interval was shorter for patients
with stage IV disease compared with those with stage IIc to
IV disease (median, 14 v 21 days; range, 6 to 47 v 3 to 62
days; P .0419).
Sixteen patients experienced disease progression early
during first-line chemotherapy. After the sixth cycle of che-
motherapy, 102 patients achieved a pathologic complete
response at second-look surgery, 98 patients obtained a
clinical complete response but were not submitted to
second-look surgery, and 113 patients had clinically or
surgically detectable persistent disease. Therefore, taking
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into consideration the best assessed response, a complete
(either clinical or pathologic) response was observed in
200 patients.
Residual disease ( 1 v  1 cm) and ascites (absent v
present) were the only variables related to the chance of
achieving a complete response to chemotherapy at both
univariate (P .0001 and P .0002, respectively; Table 1)
and multivariate analysis (P .0001 and P .003, respec-
tively; Table 2), whereas the interval from primary surgery
to chemotherapy had no predictive value.
By log-rank test, overall survival was related to resid-
ual disease ( 1 cm v  1 cm; P  .0003; Fig 1), ascites
(absent v present; P .0161; Fig 2), and tumor stage (IIc
to III v IV; P  .0055; Fig 3), but not to interval from
primary surgery to chemotherapy (Fig 4), age (data not
shown), histologic type (data not shown), and histologic
grade (data not shown).
The nonparametric correlation between time inter-
val from primary surgery to the start of chemotherapy
and overall survival did not show any statistical signifi-
cance (Spearman rank correlation coefficient rS  0.02;
P  ns; Fig 5).
The Cox proportional hazards model showed that
residual disease (P  .001) and tumor stage (P  .04)
were the only independent prognostic variables for over-
all survival (Table 3).
DISCUSSION
Cytoreductive surgery followed by paclitaxel- plus platinum-
based chemotherapy represents the standard treatment for
patients with advanced epithelial ovarian cancer. Cur-
rent regimens are able to obtain a clinical complete re-
sponse rate of approximately 50%, a pathologic complete
response rate of 25% to 30%, a median progression-free
survival of 15.5 to 22months, and amedian overall survival of
31 to 44 months.36-44 Randomized studies comparing pacli-
taxel plus cisplatin versus paclitaxel plus carboplatin showed
that the two regimens are equally effective; the carboplatin
combination is well tolerated.37,41,42,44 A recent randomized
studyrevealednodifference inresponse rates,progression-free
survivals, and early survival data between docetaxel plus car-
boplatin versus paclitaxel plus carboplatin, whereas a signifi-
cant difference in toxicity profiles emerged between the two
regimens, with less neurotoxicity andmoremyelosuppression
for docetaxel plus carboplatin.45,46 Several ongoing phase III
Table 1. Variables Predictive of Complete Response to Taxane- Plus Platinum-Based Chemotherapy (univariate analysis)
Variable
Complete
Responders
No. of
Patients % P
Age, years
 56 100 158 63.2 NS
 56 100 155 64.5
Stage
II-III 179 273 65.6 NS
IV 21 40 52.5
Grade
G1-G2 59 90 65.6 NS
G3 141 223 63.2
Histologic type
Serous 133 205 64.8 NS
Nonserous 67 108 62.0
Residual disease
 1 cm 109 138 78.9  .0001
 1 cm 91 175 52.0
Ascites
No 76 96 79.1 .0002
Yes 124 217 57.1
Interval time from primary surgery to the start of
chemotherapy, days
 11 51 86 59.3
12–21 49 77 63.6
22–31 48 75 64.0 NS
 31 52 75 69.3
Abbreviation: NS, not significant.
The 200 complete responders included the 102 pathologically complete responders and the 98 clinically complete responders who did not undergo
surgical reassessment.
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studies are assessing whether the addition of other drugs to
paclitaxel and carboplatin provides a clinical benefit.43
Residual disease after initial surgery is the most impor-
tant prognostic factor for advanced epithelial ovarian
cancer.2-6 For instance, according to the FIGO Annual Re-
port No. 24, the 5-year survival rates in stage IIIc disease
were 55%, 42.3%, and 15.2%, respectively, for patients with
nomacroscopic residuum,macroscopic residuum less than
2 cm, and residuum more than 2 cm.1 Several other clini-
copathologic and biologic variables have been related to the
clinical outcome of patients with this malignancy,2-21
whereas the predictive and prognostic relevance of the in-
terval time from primary surgery to the start of chemother-
apy has not yet been clarified.33,35 There are little data
regarding the effectiveness of chemotherapy in relation to
timing of such therapy from surgery in animal tumor
models27-29 as well as in human malignancies including
epithelial ovarian cancer.30-35 By assessing how a variation
in the time interval between primary tumor removal and
cyclophosphamide administration affected residual tumor
cell kinetics and animal survival in a murine mammary
adenocarcinoma, Fisher et al27 detected that the shorter the
time after operation that therapy is begun, the more com-
plete is the abrogation of the kinetic changes in distant
tumor foci, the more effective becomes the suppression of
residual tumor burden, and the more prolonged is the
survival. When cyclophosphamide was given before the
operation, it completely prevented the increase in labeling
index resulting from tumor removal, and prolonged mice
survival to the greatest extent. In a murine osteosarcoma
model, the perioperative administration of cytotoxic drugs
demonstrated a significant advantage in preventing sys-
temic relapses when compared with postoperative chemo-
therapy.28 Conversely, in the study of Berg et al29 there was
no significant difference in survival between dogs with os-
teosarcoma that began cisplatin and doxorubicin chemo-
therapy 2 days after amputation and those that started
chemotherapy 10 days after surgery.
In a series including 460 stage I and II breast cancer
patients who received adjuvant chemotherapy consisting of
fluorouracil, doxorubicin, and cyclophosphamide, there
was no difference in 4-year disease-free survival for patient
subgroups with interval times from surgery to chemo-
therapy of less than 10 weeks, 10 to 13, 14 to 17, or  18
weeks (64%, 68%, 60%, and 63%, respectively).30 Con-
versely, in the study of Pronzato et al,32 which enrolled
Table 2. Variables Predictive of Complete Response to Taxane- Plus Platinum-Based Chemotherapy (multiple logistic regression)
Variable
Parameter
Estimate SE Wald 2 P OR 95% CI
Intercept 1.8987 0.2994 40.2272  .0001
Residual disease 1.1342 0.2627 18.6367  .0001 3.109 1.858 to 5.202
Ascites 0.8771 0.2957 8.7954 .0030 2.404 1.346 to 4.292
Abbreviation: OR, odds ratio.
Fig 1. Overall survival in patients with
advanced epithelial ovarian cancer by re-
sidual disease after primary surgery.
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229 patients with node-positive primary operable breast
cancer who underwent adjuvant chemotherapy consisting
of fluorouracil, methotrexate, and cyclophosphamide, sur-
vival was significantly improved in patients who began che-
motherapy within 35 days from surgery compared with
those who started adjuvant treatment later (P .01). Col-
leoni et al34 investigated the relationship between early ini-
tiation of chemotherapy, estrogen receptor (ER) status, and
prognosis in 1,788 premenopausal, node-positive patients
treated on different International Breast Cancer Study
Group trials. Among patients with ER-negative tumors,
10-year disease-free survival was 60% for patients who
started chemotherapy within 20 days compared with 34%
for those who started chemotherapy later (P  .0003).
Conversely, timing of chemotherapy initiation had no
prognostic relevance for patients with ER-positive tumors.
For epithelial ovarian cancer, in the cohort study of
Warwick et al33 including 362 patients with advanced dis-
ease treated with surgery followed by platinum-based che-
motherapy, those patients with a longer interval appeared
to have a worse outcome, but the interval was not an inde-
pendent prognostic factor at multivariate analysis. The
Scottish Gynaecological Cancer Trials Group investigated
whether the length of the interval from primary surgery to
Fig 2. Overall survival in patients with ad-
vanced epithelial ovarian cancer by ascites.
Fig 3. Overall survival in patients with
advanced epithelial ovarian cancer by In-
ternational Federation of Gynecology and
Obstetrics stage.
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chemotherapy has any effect on the progression-free sur-
vival of 472 patients enrolled onto four studies who had all
received platinum-containing chemotherapy in combina-
tion with either a taxane (paclitaxel or docetaxel) or with
cyclophosphamide.35 The median interval from surgery to
chemotherapy was 22 days (range, 5 to 113 days). Univari-
ate analysis showed a trend for worse progression-free sur-
vival for patients with earlier therapy, but women treated
earlier tended to have bulkier residual disease. Therefore,
multivariate analysis revealed that the interval from surgery
to chemotherapy is not an independent prognostic factor
for progression-free survival.
The predictive or prognostic relevance of a variable
should be assessed in a group of patients who receive ho-
mogenous treatments. In our study, we investigated the
clinical relevance of time interval from primary surgery
to chemotherapy in a series of 313 patients with advanced
epithelial ovarian cancer who had all undergone taxane-
plus platinum-based chemotherapy. The 25%, 50%, and
75% quantiles of intervals were 11, 21, and 31 days,
respectively. Residual disease after initial surgery and the
absence or presence of ascites were independent predic-
tive factors for the chance of achieving a complete re-
sponse, whereas residual disease and tumor stage were
Fig 4. Overall survival in patients with ad-
vanced epithelial ovarian cancer by interval
time from primary surgery to the start of
taxane- plus platinum-based chemotherapy.
Fig 5. Relationship between interval
time from primary surgery to the start of
taxane- plus platinum-based chemother-
apy and overall survival (nonparametric
correlation analysis).
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independent prognostic variables for overall survival.
Conversely, statistical analyses failed to detect significant
differences in complete response rates and survival among
patients with time interval from surgery to chemotherapy
shorter than 11, 12 to 21, 22 to 31, and longer than 31 days.
From a theoretical viewpoint, residual lesions after cy-
toreductive surgery have a high growth fraction, and there-
fore the earlier the start of chemotherapy, the greater is the
chance that chemotherapy controls residual disease. The
currently available chemotherapy regimens obtain satisfac-
tory response rates in patients with advanced epithelial
ovarian cancer, but most responders will subsequently ex-
perience tumor recurrence and up to more than 80% of
patients will need a second-line treatment for
chemotherapy-resistant disease.47,48 Drug resistance is the
major obstacle in developing systemic therapies for ad-
vanced cancer and might be involved particularly in the
secondary treatment failure frequently seen in epithelial
ovarian cancer.49-51 On the basis of somatic mutation the-
ory, it can be hypothesized that resistant mutants arise
spontaneously early in the natural history of cancers and
that the likelihood of developing genetically resistant clones
is closely related to cell number.52 The onset of permanent
resistance accounts for the inverse relationship between cell
number and curability by drugs. At the time of clinical
detection, advanced epithelial ovarian cancer consists of
1012 to 1013 tumor cells and therefore often contains a high
rate of genetically chemotherapy-resistant clones. This can
explain why an early administration of chemotherapy after
surgery seems to give no clinical benefit when compared
with a more delayed treatment.
In the clinical practice, the start of chemotherapy can
be delayed because of different situations, such as when
patients are referred from other institutions some weeks
after surgery; when patients are submitted to aggressive
cytoreductive surgery with consequent recovery delay;
when patients present low hemoglobin levels and need
more time to recover after surgery; when patients need to be
discharged home earlier after surgery to get adjusted to
their cancer diagnosis before starting chemotherapy that
can be administered in a outpatient facility; and in diffi-
cult cases for the pathologist, for which the morpholog-
ical interpretation is not unequivocal and more time is
required for additional investigations (ie, immuno-
histochemistry and molecular analysis) to define with
certainty the histologic type of the tumor. Only a pro-
spective, specifically planned study can definitely clarify
the clinical relevance of interval time between surgery
and chemotherapy. However, the currently available
data failed to detect that a few weeks of delay in starting
chemotherapy influences the clinical outcome of patients
with advanced epithelial ovarian cancer.
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